Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of chronic diseases, robust pipeline in human microbiome therapeutics market, and side effects of existing treatments for heath disorders.
The human microbiome therapeutics market is segmented as below:
By Product
- Probiotics
- Prebiotics
- Medical foods
- Prescription drugs
By Application
- Gastrointestinal disorders
- Infectious diseases
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the human microbiome therapeutics market covers the following areas:
- Human microbiome therapeutics market sizing
- Human microbiome therapeutics market forecast
- Human microbiome therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global human microbiome therapeutics market: 4D pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increase in industry-academia collaboration for development of novel therapeutics.'
According to the report, one of the major drivers for this market is the growing prevalence of chronic diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D pharma Plc
- BiomX Inc.
- Eligo Bioscience
- ENTEROME SA
- Evelo Biosciences Inc.
- Evogene Ltd.
- Ferring BV
- Finch Therapeutics Group Inc.
- Flightpath Biosciences
- Johnson and Johnson Services Inc.
- MaaT Pharma
- Microbiotica Ltd.
- OptiBiotix Health Plc
- PureTech Health Plc
- Second Genome Therapeutics
- Seres Therapeutics Inc.
- Synlogic Inc.
- Takeda Pharmaceutical Co. Ltd.
- YSOPIA Bioscience
- Locus Biosciences Inc.